Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received a consensus rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $38.00.

INO has been the topic of a number of recent analyst reports. Oppenheimer dropped their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. HC Wainwright dropped their price objective on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Monday, November 18th. Finally, Royal Bank of Canada dropped their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 15th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Barclays PLC grew its stake in shares of Inovio Pharmaceuticals by 282.6% in the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 25,116 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Inovio Pharmaceuticals by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $379,000. State Street Corp grew its stake in shares of Inovio Pharmaceuticals by 11.7% in the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after purchasing an additional 51,414 shares during the last quarter. Finally, Atom Investors LP purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $103,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Down 7.3 %

INO stock opened at $2.15 on Thursday. The business’s 50-day moving average is $4.82 and its two-hundred day moving average is $7.05. Inovio Pharmaceuticals has a 1 year low of $2.04 and a 1 year high of $14.75.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.